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Introduction
There are at least 60 rare inherited diseases affecting the
kidney, which, although individually affecting less than one
person in every 2000, have a large negative impact on the
quality of life of the patients, often children, and their fam-
ilies [1,2]. The care of patients with rare nephropathies
is hampered by major problems. Most of the diseases are
chronically debilitating conditions, and some are life threat-
ening. Their rarity and the phenotype variability imply lim-
ited knowledge of the underlying mechanism(s) and natu-
ral course, lack of standardization of diagnostic procedures
and fragmentation of the clinical and biological data col-
lections, with small cohorts restricting the power of clinical
studies [3,4]. Furthermore, the low prevalence implies a
lack of priority for the pharmaceutical industry and even
public funding [5]. The establishment of multidisciplinary
projects gathering a critical mass of expertise and patients,
at the European level, is thus essential to maximize the
impact of research on rare diseases [3].
EUNEFRON (the European Network for the Study of
Orphan Nephropathies) is a consortium that has beenmobi-
lized in response to the Call HEALTH-2007-2.4.4-1 (‘Nat-
ural course and pathophysiology of rare diseases princi-
pally affecting the genitourinary tract’) of the framework 7
(FP7) programme for health of the European Union. The
research programme, which involves 12 research groups
from 10 academic institutions in 8 European countries
(Figure 1), has been launched on 1 May 2008, for an initial
duration of 4 years and with a total budget of 6 million
euros.
Rationale and aims of the EUNEFRON
consortium
Despite significant research efforts, our understanding of
the natural course and pathophysiology of rare inherited
diseases of the kidney remains limited. Some of the genes
mutated in these diseases are involved in renal structure
and function, but we know much less about the regulatory
pathways they act in or about the molecular and cellular
mechanisms that cause their malfunction in renal disease.
As a result, little progress has been made towards improved
diagnosis and therapy of these conditions. Although indi-
vidual areas of expertise in rare diseases exist in Europe, in-
sufficient coordination between groups and fields may pose
a threat to the understanding of such conditions, both at the
clinical and mechanistic level, delaying the development of
novel diagnostic and therapeutic tools. Accordingly, there
is a growing interest in coordinating research and collecting
information pertinent to rare inherited nephropathies across
Europe [3–5].
The aim of EUNEFRON is to mobilize a critical mass of
expertise to investigate, on a Europe-wide scale, the natural
history and pathophysiology of a series of rare inherited dis-
eases of the kidney. The project will exploit the technologi-
cal opportunities of the post-genome era and the knowledge
generated through existing networks and projects funded by
the FP6, including EuReGene, the EuropeanRenal Genome
project [5]. In particular, EUNEFRON will use in vitro and
in vivo models to pursue specific objectives in 16 diseases
affecting the glomerulus, the proximal tubule (PT), the thick
ascending limb (TAL), the distal convoluted tubule (DCT)
and the collecting duct (CD) (Figure 2). These diseases are
caused by mutations in 20 genes that encode proteins in-
volved in awide range of functions, including enzymatic ac-
tivities, transport mechanisms, structure and transcriptional
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Fig. 1. EUNEFRON: Geographic distribution of the 10 participating academic institutions (12 research groups) in 8 European countries.
Fig. 2. Details of the 16 rare inherited nephropathies that are investigated in EUNEFRON, grouped by segment/topic. These diseases are caused by
mutations in 20 genes (indicated in italics) that encode proteins involved in a wide range of functions (enzyme, transport, structure, transcription, etc.).
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Fig. 3. Structure of the EUNEFRON project. Studies in Topics 1 to 5
will provide insights into the natural course and pathophysiology of the
rare nephropathies. Topic 6 will integrate the relevant information into a
registry, while establishing a network of genetic laboratories. The man-
agement and dissemination activities (Topic 7) provide constant support
for the research activities and dissemination of knowledge.
regulation. The proposal also aims at initiating a Euro-
pean registry and a network of genetic laboratories to foster
interactions between physicians and researchers, promote
clinical and basic research and ensure efficient diagnostic
procedures. It includes a comprehensive strategy of dis-
semination, involving patient organizations and experts in
ethics and socio-economics, biobanking and drug develop-
ment. By increasing our knowledge of these rare diseases,
EUNEFRON should help to develop preventive, diagnostic
and therapeutic interventions for these rare diseases and
yield new insights into renal disease progression, blood
pressure control, prevention of renal stones, effect of gen-
der and ageing and multi-systemic involvement of renal
diseases.
Overall structure of the programme
The EUNEFRON consortium integrates experts in genet-
ics, clinical nephrology (adult and pediatric), physiology
and cell/molecular biology from 12 research groups. The
use and development of disease models, including trans-
genic mice andmodel organisms such as theXenopus laevis
tadpole, the expertise in genetics and phenotype character-
ization and the availability of registries and cohorts were
considered crucial for this programme. The specific objec-
tives are organized in five topics according to the nephron
segment concerned. The data generated in these topics will
be integrated in a registry, and a network of genetic laborato-
ries will be implemented. Management and dissemination
will support all activities within the consortium and will
provide support for dissemination of knowledge (Figure 3).
The topic coordinators and the project coordinator form
the Steering Committee of the programme, which is sup-
ported by the Project management office and by Panels set
up for ethics/society, training and exploitation/intellectual
property rights (IPR). An external Advisory Board provides
guidance to the Steering Committee. All principal investi-
gators in EUNEFRON constitute the General Assembly, the
ultimate decision-making body of the programme.
Specific objectives of EUNEFRON
Disorders of the glomerulus
This topic is focused on rare diseases affecting the podocyte,
including steroid-resistant nephrotic syndrome caused by
mutations in NPHS2, the gene coding for podocin [6],
and fetomaternal alloimmunizationwith antenatal glomeru-
lopathy (FMAIG), an alloimmune disorder resulting from
maternal antibodies directed against neutral endopepti-
dase that cross the placenta and bind to fetal glomeru-
lar podocytes [7]. These disorders provide the opportunity
to analyse ‘pure’ podocyte pathobiology, irrespective of
confounding factors. We will also investigate the pathogen-
esis of disorders due to defective type IV collagen, includ-
ing Alport syndrome [8] and the newly described Heredi-
tary Angiopathy with Nephropathy, Aneurism and Cramps
(HANAC) syndrome [9], as well as therapeutic modalities
in Fabry Disease [10].
Disorders of the proximal tubule
We will use cell and mouse models and registries to inves-
tigate cystinosis, the most common inherited type of renal
Fanconi syndrome. Cystinosis is an autosomal recessive
disorder characterized by defective lysosomal efflux of cys-
tine, caused by inactivatingmutations in theCTNS gene that
encodes the cystine transporter cystinosin [11]. In particu-
lar, we will seek to understand the influence of lysosomal
cystine accumulation on PT cell phenotype, including ox-
idative stress and adaptation to specific therapies. We will
also investigate disorders affecting the endocytic activity of
PT cells, including Dent’s disease, a X-linked form of renal
Fanconi syndrome associated with hypercalciuria, kidney
stones and progressive renal failure, caused by mutations
in the CLCN5 gene coding for the endosomal Cl−–H+ ex-
changer ClC-5 [12,13]. Other disorders with defective PT
endocytosis include cystic fibrosis, due to recessive muta-
tions in the CFTR Cl− channel [14]; Imerslund Gra¨sbeck
disease, a rare autosomal recessive disorder caused by vi-
tamin B12 (cobalamin) malabsorption with tubular protein-
uria, caused bymutations in the cubilin (CUBN) or amnion-
less (AMN) genes that code for endocytic receptors located
in intestine and PT cells [15] and Maturity Onset Diabetes
of the Young (MODY3), an autosomal dominant form of
diabetes caused by heterozygous mutations in TCF1, a gene
that encodes the transcription factorHNF1α [16]. This topic
will also address the tubular component of the basalopathy
associated with HANAC [9].
Disorders of the thick ascending limb of Henle’s loop
We will develop novel mouse models and cell culture sys-
tems to provide insights into disorders of the TAL, in-
cluding familial hypomagnesaemia with hypercalciuria and
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nephrocalcinosis (FHHNC), caused by mutations in the
CLDN16 and CLDN19 genes coding for the tight junc-
tion proteins claudin-16 and claudin-19 [17,18], and famil-
ial juvenile hyperuricemic nephropathy (FJHN, also named
medullary cystic kidney disease type 2, MCKD2). FJHN is
caused by mutations in UMOD, the gene encoding Tamm–
Horsfall protein (uromodulin), the most abundant protein
in the normal urine [19,20]. Mutations in uromodulin lead
to its intracellular accumulation, followed by interstitial
nephritis and tubular damage [20]. A better understanding
of these mechanisms is relevant for urinary concentration
defects, interstitial nephritis and kidney stones [21].
Disorders of the distal convoluted tubule
This topic will investigate the pathophysiology of Gitel-
man’s syndrome (GS) and pseudohypoaldosteronism type II
(PHA2, orGordon syndrome). GS is an autosomal recessive
disorder causing salt wasting and secondary aldosteronism,
with hypomagnesaemia and hypocalciuria, due to inactivat-
ing mutations in SLC12A3 that codes for the Na+–Cl− co-
transporter NCCT [22,23]. PHA2 is an autosomal dominant
disorder characterized by hypertension and hyperkalaemia,
i.e. a phenotype that is opposite toGS [24].Mutations in two
members of the WNK kinase family, WNK1 and WNK4,
have been involved in PHA2 through their coordinated reg-
ulation of NCCT [25]. These investigations will yield new
disease models and insights into regulation of blood pres-
sure, response to diuretics and transport mechanisms (e.g.
Ca2+ and Mg2+ handling) in the DCT [26,27].
Disorders of the collecting duct
The CD consists of principal cells and intercalated cells
that play essential roles in fine-tuning the sodium/water and
acid–base homeostasis, respectively. Mutations in AVPR2
and AQP2 genes that encode the vasopressin type 2 re-
ceptor (V2R) and the aquaporin-2 (AQP2) water channel,
respectively, cause nephrogenic diabetes insipidus (NDI), a
disorder in which the antidiuretic response to vasopressin
is lacking, resulting in polyuria and polydipsia [28]. An-
ion exchanger proteins (AE1, pendrin) and vacuolar H+-
ATPase control blood pH and cause distal renal tubular
acidosis (dRTA) when mutated [29,30]. We will investigate
the genotype–phenotype correlations and the molecular ba-
sis underlying dRTA and study the role and interactions of
pendrin, AE1 interacting proteins and ammonium trans-
porters [31]. Patients with NDI will be analysed, and we
will test whether V2R (ant)agonists are able to rescue their
encoded V2R mutants [32].
Registry and network of genetic laboratories
Rare diseases show a significant phenotypic and genetic
heterogeneity, which hampers their clinical characteriza-
tion and the initiation of therapeutic trials. The collabora-
tion of expert clinical centres in EUNEFRONwill facilitate
the centralization of clinical and biological information
based on a large recruitment of patients through the cre-
ation of a European registry and a network of genetic lab-
oratories [3,4]. The registry will be a critical tool to im-
prove our knowledge of the natural course of the disease;
to facilitate the dissemination of information; to promote
basic and clinical investigations and to improve clinical
care and follow-up of the patients. As part of this pro-
gramme, we will extend the UK Cystinosis Registry to
other European centres, with special attention to gender
and ageing aspects, effect of cysteamine and additive ther-
apies. Initiating a European network of genetic laboratories
should improve the procedures for genetic diagnosis, sim-
plify access to genotyping and facilitate the search for new
genes.
Dissemination of knowledge through EUNEFRON
EUNEFRON will organize public symposia on rare inher-
ited nephropathies (the first scheduled in Zurich, 18 April
2009; see www.eunefron.org), training courses covering
strategic technologies and short-term fellowships for sci-
entists. Participants will get training on IPR, gender issues
in research and ethics and social issues in rare diseases.
The programme has created a website (www.eunefron.org)
which facilitates contacts between partners and contains
information relevant to the outside scientific community,
including the scientific projects, the diseases investigated,
repositories (animal models, cell lines), novel tools (an-
tibodies, probes) and methodologies and the registry and
the network of genetic laboratories. The website will also
inform about educational activities and will contain infor-
mation relevant to patient advocacy groups, healthcare pro-
fessionals, the legislature and the interested public. All ac-
tivities within the consortium are linked to national and
European initiatives (e.g. Orphanet) in the area of rare dis-
eases. Interested physicians and health care professionals
are invited to contact consortium members for patient re-
ferrals or additional information.
Expected results
After 4 years, the work programme of EUNEFRON
should bring novel discovery tools including model
organisms, transgenic mice and cell culture systems.
These tools will provide insights into the natural course,
genotype–phenotype correlations and pathophysiology of
rare nephropathies, with relevance for acquired renal dis-
eases and multi-systemic complications, providing new tar-
gets for diagnosis and therapeutic intervention. Initiation of
a registry will facilitate the translation of insights into pa-
tient care, by improving phenotype standardization and fos-
tering studies of the natural course and genotype–phenotype
correlations on a Europe-wide scale. Similarly, a network
of genetic laboratories should facilitate access to genotyp-
ing, standardize and improve the procedures and pave the
way for new gene discovery. These new tools will be ac-
cessible throughout the scientific and health care commu-
nity in accordance with the ethical guidelines. The web-
site, educational activities and exchanges organized through
EUNEFRON should increase the awareness of patients,
health care providers and scientists for rare inherited
nephropathies in Europe.
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